Table 1. Characteristics, summary of treatment and immune responses, and survival for the individual patients.

		Characteristics (baseline)			Treatment weeks 1–12		Follow-up and survival
Dose group	Patient No.	Age (sex)	KPS (%)	Tumour site/metastasisa (+/−)	No. of Injections/ Completed study	Immune-responses DTH/T cells	No. of booster injections	DTH	Survival days from start of treatment
Low	1	69 (M)	85	cap/+	6/no	−/−	—	—	28
	2	69 (M)	100	cap/−	8/yes	+/−	—	—	144
	3	64 (M)	80	cap, cor/−	7/no	−/−	—	—	40
	4	61 (F)	70	cap/+	8/yes	−/−	—	—	190
	5	61 (M)	100	cau, cor/+	6/no	−/−	—	—	31
	7b	60 (F)	85	cau, cor/+	5/no	−/−	—	—	20
	8	59 (F)	85	cap/+	8/yes	+/−	—	—	146
	9c	37 (M)	85	cor/+	6/no	−/−	—	—	94
	10b,d	59 (F)	100	cap/−	4/no	−/−	—	—	290
	11b	47 (M)	70	?/+	1/no	−/−	—	—	3
	12	59 (M)	100	cap/−	8/yes	+/−	3	−	243
Intermediate	101	73 (F)	95	cap/+	8/yes	+/−e	6	+	325
	102	55 (F)	95	cor, cau/−	8/yes	+/+	7	+	362
	103	58 (F)	95	cap/+	8/yes	+/−	2	−	133
	104	64 (F)	95	cap/−	8/no	−/+	—	—	68
	105	58 (M)	95	cap/+	8/yes	+/+	3	+	189
	106	49 (M)	85	cor/+	7/no	−/−	—	—	80
	107	73 (M)	85	cau/+	8/no	−/−	—	—	132
	108	56 (M)	95	cap/+	8/yes	+/+	10	+	381
	109c	68 (M)	95	?/?	6/no	−/nt	—	—	228
	110	59 (M)	90	cor, cau/−	8/yes	−/−	4	−	292
	111	68 (M)	100	cap/−	8/yes	−/+	2	−	337
	112	67 (F)	95	cap/−	8/yes	+/+	1	−	199
	113	58 (M)	95	cap/−	8/yes	−/+	2	+	432
	114b	71 (F)	95	cau/+	5/no	−/nt			23
	115	60 (F)	90	cap/−	8/yes	+/+	13	+	575
	116	66 (F)	95	cau/−	8/yes	+/+	6	−	323
	117	69 (M)	90	cap/−	8/yes	+/−	—	—	91
High	201	45 (F)	80	cap/−	10/yes	+/+	—	—	320
	202	58 (M)	85	cor, cau/−	8/yes	+/+	—	—	165
	203b	54 (F)	85	cap/+	2/no	−/nt	—	—	27
	204	70 (F)	90	cap/+	7/no	−/nt	—	—	53
	205b	42 (F)	70	cap/+	4/no	−/nt	—	—	10
	206b	49 (M)	75	cor, cau/+	4/no	−/nt	—	—	12
	207	58 (F)	95	cap/−	8/no	−/−	—	—	82
	208	75 (M)	95	cap/−	8/yes	−/+	6	−	307
	209	54 (M)	80	?/?	8/yes	−/+			121
	210	53 (F)	85	cor/+	7/no	−/−			75
	211	73 (M)	95	cor/−	8/yes	−/−	4	−	249
	212b,f	40 (F)	90	cor/−	8/yes	−/+	1	−	120
	213b,f	68 (F)	95	cap/−	8/yes	+/+	3	−	176
	214	56 (M)	85	cor/−	8/yes	−/−	2	+	154
	215	64 (M)	90	cap/−	8/yes	−/+	—	—	119
	216	58 (M)	90	cap/−	8/yes	−/+	1	−	153
	217b	63 (M)	75	cap/+	4/no	−/−	—	—	12
	218	46 (M)	90	cap/−	8/yes	−/+	—	—	106
	219	72 (F)	95	cor/+	8/yes	−/+	8	−	365
	221	70 (F)	95	cap, cor/−	8/yes	+/+e	5	+	233

DTH=delayed-type hypersensitivity; KPS=Karnofsky performance status; nt=not tested; na=not applicable; cap=caput; cau=cauda; cor=corpus; ?=unknown.

^a81% of patients with metastasis had liver metastasis.

^bNot evaluable.

^cWithdrawn to other treatment after week 4.

^dWithdrawn to surgery.

^ePositive at base line.

^fEarlier resected patient.